GlassScriptPhysician profile
Michael J Sundborg
NPI 1508857962
$85,420.29
in general payments reported to CMS, 2019-2025
22 companies · $1,970 in 2025
The $1,970 reported for 2025 was more than what 78% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40K · 2020: $172 · 2021: $7,171 · 2022: $25K · 2023: $5,655 · 2024: $5,540 · 2025: $1,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,170 · Food and Beverage: $2,510 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400 · Travel and Lodging: $1,020 · Education: $64.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,170.00 |
| Food and Beverage | $2,510.05 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
| Travel and Lodging | $1,020.20 |
| Education | $64.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $39,747.25 | 2019 | |
| Glaxosmithkline, LLC. | $37,155.99 | 2021-2025 | Jemperli, Zejula |
| Astrazeneca Pharmaceuticals LP | $5,232.94 | 2019-2025 | Lynparza |
| Intuitive Surgical, INC. | $1,750.55 | 2020-2025 | |
| Genmab U.S., INC. | $285.48 | 2021-2025 | Tivdak |
| Eisai INC. | $284.66 | 2022-2025 | |
| Smith+Nephew, INC. | $179.93 | 2021-2025 | Grafix Pl, Stravix, Oasis |
| Merck Sharp & Dohme LLC | $154.68 | 2022-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Menarini Silicon Biosystems, INC. | $125.00 | 2024 | |
| Astellas Pharma US INC | $122.36 | 2024-2025 | Veozah |
| Myriad Genetic Laboratories, INC. | $105.18 | 2022-2023 | Precisetumor, Myrisk |
| Abbvie INC. | $91.73 | 2024-2025 | |
| Ethicon US, LLC | $32.74 | 2025 | Evarrest |
| Daiichi Sankyo INC. | $29.31 | 2025 | Enhertu |
| Immunogen, INC. | $28.68 | 2023 | Elahere |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $22.62 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $19.65 | 2019 | |
| Novartis Pharmaceuticals Corporation | $19.37 | 2023 | |
| Clovis Oncology, INC. | $18.25 | 2022 | |
| Foundation Medicine, INC. | $13.92 | 2023 | Foundationone Liquid Cdx |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sundborg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.